Next Phase Newsletter

A venture capital firm that currently manages 2 funds makes equity and mezzanine investments into venture stage companies in the life science space ranging from $1 -10 million over the lifetime of the investment. The firm has a geographical focus on companies in Western Europe plans to make 2-3 investments over the next 6-9 months.

The firm is looking for companies in the Therapeutics, Diagnostics and Medical Technology spaces. While the firm considers all subsectors and indications, including orphan indications, they are especially interested in the vaccine field. The firm generally looks for companies that have proof of concept from animal studies generally investing in Series A rounds. The firm is very open to repurposed and reformulations and they generally only consider investment into biosimilars when a strong case for a high value inflection point can be made.

The firm looks for experienced management teams and generally looks to take a board seat. The firm often leads or co-leads investment rounds always looking to take an active role in the development of its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech sector fund with headquarters in China is equipped with state-of-the-art instruments housed by modern laboratories in an artistically designed building. The firm works with top ten largest global pharmaceutical companies and small to medium sized US and Europe-based businesses in studies of gene-to-structure, in vitro and in vivo assays, target ID, ADME, animal models, and more.

The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 10-12 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Medical Devices or Digital Health companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A US fund invests in early-stage startups in many industries with a preference for healthcare and IT technology. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office that has been actively investing for several years, is supported by well-established Chinese partners and supports companies in venturing globally. To date, the firm has made over 20 investments, mostly in the medical device space. The firm focuses on making seed investments up to $500K, with $200K being the average check size. The firm is open to global opportunities.

The firm invests across all sectors of life sciences, including therapeutics, medical devices, diagnostics, and digital health, with most of its investments having been in medtech companies. The firm is technology agnostic and is open to all kinds of high potential opportunities.

The firm seeks to work with management teams with strong academic credentials and significant experience in successfully launching early-stage ventures. The firm prefers to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a trans-Atlantic venture investment firm focused on building innovative Life Sciences businesses in the UK, Europe and the USA. The firm has a highly experienced team that focuses on turning break-through science into approved medicines or medical products.

The firm starts and invests in early and mid-stage companies with a first-in-class or best-in-class approach. The investments are focused in new drug discovery – small molecules, biologics and new modalities – med tech, enabling technologies and vaccines.

The firm’s team are well connected team and experienced, and the team supports each investment. The firm works in close alignment with management teams, and partners with them to realize their vision and achieve financial returns by bringing innovation to patients.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment and management company headquartered in South Korea has ~$500M assets under management, and has a strong product/partnership portfolio in oncology, cardiovascular, CNS, anti-infection, among others. The firm has invested in an early-stage cell therapy company in South Korea, and is actively seeking early-stage (Seed to Series A) investment opportunities, and will also consider investments into VC funds that have aligned interest areas. The firm seeks to invest between $1-2M with capacity for up to $5M per company for initial investment, with potential for follow-on investments for promising companies that achieve milestones. The firm is actively seeking for global opportunities.

The firm is most interested in companies developing novel drugs in oncology, immunology, and rare disease indications and/or novel platform technologies for drug development. The firm will consider different types of modalities but is most interested in small molecules and biologics. In terms of stage of development, the firm is most interested in pre-clinical or early clinical stage companies.

The firm has a preference for working with experienced management teams – significant experience in drug development or senior management in global pharma or large biotech is considered a huge plus. The firm highly prefers companies that have a strong IP portfolio.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office investment vehicle with offices in USA and Western Europe is looking to provide equity capital to USA-based therapeutic companies. The firm usually invests in Series A or B rounds, and will consider to participate in a seed round of financing. The firm’s typical deal size is variable, generally going as high as $5M for an initial investment.

The firm is currently looking for companies developing Therapeutics. The firm is opportunistic in terms of sub-sector and indication though they do have a preference for companies with platform technologies. The firm is willing to invest in companies with a lead asset in preclinical through Phase II of clinical trials. The firm’s portfolio includes oncology, the microbiome, pain, neurological and rare diseases biotech companies.

The firm looks to invest in companies with experienced management teams. The firm is capable to act as either a lead or a co-lead investor and generally seeks board or board observer rights. As a pro-active investor, The firm will assist in the growth of a company, recruit new talents, develop preclinical, clinical and IP strategies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.